Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $13.8 million.

  • Xeris Biopharma Holdings' Cash from Financing Activities rose 1678674.7% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.1 million, marking a year-over-year decrease of 6510.02%. This contributed to the annual value of $36.2 million for FY2024, which is 234228.15% up from last year.
  • Per Xeris Biopharma Holdings' latest filing, its Cash from Financing Activities stood at $13.8 million for Q3 2025, which was up 1678674.7% from $942000.0 recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Cash from Financing Activities registered a high of $78.2 million during Q1 2022, and its lowest value of -$3.1 million during Q1 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' median Cash from Financing Activities value was $398000.0 (recorded in 2024), while the average stood at $10.6 million.
  • Examining YoY changes over the last 5 years, Xeris Biopharma Holdings' Cash from Financing Activities showed a top increase of 3922480.0% in 2022 and a maximum decrease of 1880000.0% in 2022.
  • Over the past 5 years, Xeris Biopharma Holdings' Cash from Financing Activities (Quarter) stood at $125000.0 in 2021, then skyrocketed by 39224.8% to $49.2 million in 2022, then tumbled by 102.51% to -$1.2 million in 2023, then skyrocketed by 132.25% to $398000.0 in 2024, then skyrocketed by 3379.9% to $13.8 million in 2025.
  • Its last three reported values are $13.8 million in Q3 2025, $942000.0 for Q2 2025, and -$3.1 million during Q1 2025.